AVBP on Nasdaq
ArriVent BioPharma, Inc.
Price unavailable
Last updated Oct 16, 2026.
Overview
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $153.4M | $79.0M |
| General and administrative | $24.2M | $15.3M |
| Total operating expenses | $177.5M | $94.3M |
| Operating loss | -$177.5M | -$94.3M |
| Interest and investment income | $11.2M | $13.8M |
| Net loss | -$166.3M | -$80.5M |
| Unrealized gain (loss) on marketable securities | $225.0K | -$211.0K |
| Total other comprehensive gain (loss) | $225.0K | -$211.0K |
| Total comprehensive loss | -$166.1M | -$80.7M |
| Net loss per share attributable to common stockholders, basic (in dollars per share) | -$4.32 | -$2.56 |
| Net loss per share attributable to common stockholders, diluted (in dollars per share) | -$4.32 | -$2.56 |
| Weighted-average shares of common stock outstanding, basic (in shares) | 38.5M shares | 31.5M shares |
| Weighted-average shares of common stock outstanding, diluted (in shares) | 38.5M shares | 31.5M shares |
Every line of the balance sheet in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 | 2023-12-31 |
|---|---|---|---|
| Cash and cash equivalents | $45.5M | $74.3M | |
| Short-term investments | $267.3M | $144.6M | |
| Prepaid expenses and other current assets | $20.1M | $8.1M | |
| Total current assets | $332.9M | $227.0M | |
| Long-term investments | $47.7M | ||
| Right of use assets - operating leases | $13.0K | $154.0K | |
| Deferred offering costs | $69.0K | ||
| Other assets | $190.0K | $126.0K | |
| Total assets | $333.2M | $274.9M | |
| Accounts payable | $5.9M | $3.8M | |
| Accrued expenses | $20.0M | $13.3M | |
| Operating lease liabilities | $14.0K | $162.0K | |
| Total current liabilities | $25.9M | $17.3M | |
| Operating lease liabilities, net of current amount | $14.0K | ||
| Total liabilities | $25.9M | $17.3M | |
| Common stock $0.0001 par value, 200,000,000 shares authorized; 42,452,251 and 33,706,765 shares issued and outstanding at December 31, 2025 and December 31, 2024, respectively | $4.0K | $3.0K | |
| Additional paid-in capital | $711.8M | $496.2M | |
| Accumulated deficit | -$404.6M | -$238.3M | |
| Accumulated other comprehensive income (loss) | $14.0K | -$211.0K | |
| Total stockholders' equity | $307.2M | $257.7M | -$153.2M |
| Total liabilities and stockholders' equity | $333.2M | $274.9M | |
| Preferred stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Preferred stock, shares authorized (in shares) | 10.0M shares | 10.0M shares | |
| Preferred stock, shares issued (in shares) | 0 shares | 0 shares | |
| Preferred stock, shares outstanding (in shares) | 0 shares | 0 shares | |
| Common stock, par value (in dollars per share) | $0.00 | $0.00 | |
| Common stock, shares authorized (in shares) | 200.0M shares | 200.0M shares | |
| Common stock, shares issued (in shares) | 42.5M shares | 33.7M shares | |
| Common stock, shares outstanding (in shares) | 42.5M shares | 33.7M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow in the latest annual report, as filed.4
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net loss | -$166.3M | -$80.5M |
| Stock-based compensation expense | $12.5M | $3.2M |
| Amortization/Accretion of bond discounts/premiums | -$3.0M | |
| Prepaid expenses and other current assets | -$12.6M | $1.5M |
| Other assets | -$20.0K | |
| Accounts payable | $2.1M | -$751.0K |
| Accrued expenses | $6.7M | $6.4M |
| Operating lease liabilities | -$21.0K | -$2.0K |
| Net cash used in operating activities | -$160.6M | -$70.2M |
| Purchase of short-term and long-term investments | -$272.9M | -$194.2M |
| Sales and maturities of short-term and long-term investments | $201.7M | $1.7M |
| Net cash used in investing activities | -$71.2M | -$192.5M |
| Proceeds from issuance of common stock, net of issuance costs | $202.6M | $185.9M |
| Proceeds from the exercise of stock options | $502.0K | $631.0K |
| Payment of deferred financing costs | -$70.0K | |
| Net cash provided by financing activities | $203.1M | $186.6M |
| Net decrease in cash and cash equivalents | -$28.8M | -$76.1M |
| Deferred offering costs transferred to additional paid-in-capital | $300.0K | $2.7M |
Recent filings
- Oct 13, 20268-K
- Oct 13, 2026SCHEDULE 13G
- Oct 8, 2026SCHEDULE 13D/A
- Oct 6, 20268-K
- Aug 12, 20268-K
- Aug 12, 202610-Q
- Jul 27, 2026SCHEDULE 13G/A
- Jun 22, 20268-K
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- Jun 22, 20264 OWNERSHIP DOCUMENT
- May 11, 20268-K
- May 11, 202610-Q
- May 11, 2026424B5
Every filing from the last three years, summarized. The full record is on SEC EDGAR.1
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6